title: [Targeted therapies in breast cancer: current status and perspectives].
abstract: The introduction of targeted therapies has largely modified the treatment strategies in oncology. Two targets are currently used for defining the systemic treatment of breast cancer: hormone receptors and HER2 overexpression. Trastuzumab, a monoclonal antibody, is the only registered antiHER2 treatment in Belgium. The association of trastuzumab with chemotherapy is now the recommended adjuvant treatment for early breast cancer overexpressing HER2. Other antiHER2 medications are available and some will probably be registered soon. Angiogenesis is another potential target for improving the treatment results. The CHU Liège, as a reference center for the systemic treatment of solid tumors, participates in many international trials in order to validate these new approaches. The highest quality of care is required to be in compliance with the conduct of these clinical trials. Another benefit for the patient is the easy access to last generation medical treatments, generally not accessible in our health care system in Belgium outside of clinical trials.
authors.affiliation: CHU Sart Tilman, Liège, Belgique.
authors.forename: G
authors.initials: G
authors.lastname: Jerusalem
authors.forename: A
authors.initials: A
authors.lastname: Rorive
authors.forename: C
authors.initials: C
authors.lastname: Gennigens
authors.forename: B
authors.initials: B
authors.lastname: Sautois
authors.forename: C
authors.initials: C
authors.lastname: Mievis
authors.forename: G
authors.initials: G
authors.lastname: Fillet
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D018734:Genes, erbB-2 / Q000187:drug effects; D006801:Humans
chemical_list: D020533:Angiogenesis Inhibitors